CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 30 11 2022
revised: 07 04 2023
accepted: 20 06 2023
medline: 4 9 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: ppublish

Résumé

Patterns of receptors for chemotactic factors regulate the homing of leukocytes to tissues. Here we report that the CCRL2/chemerin/CMKLR1 axis represents a selective pathway for the homing of natural killer (NK) cells to the lung. C-C motif chemokine receptor-like 2 (CCRL2) is a nonsignaling seven-transmembrane domain receptor able to control lung tumor growth. CCRL2 constitutive or conditional endothelial cell targeted ablation, or deletion of its ligand chemerin, were found to promote tumor progression in a Kras/p53Flox lung cancer cell model. This phenotype was dependent on the reduced recruitment of CD27- CD11b+ mature NK cells. Other chemotactic receptors identified in lung-infiltrating NK cells by single-cell RNA sequencing (scRNA-seq), such as Cxcr3, Cx3cr1, and S1pr5, were found to be dispensable in the regulation of NK-cell infiltration of the lung and lung tumor growth. scRNA-seq identified CCRL2 as the hallmark of general alveolar lung capillary endothelial cells. CCRL2 expression was epigenetically regulated in lung endothelium and it was upregulated by the demethylating agent 5-aza-2'-deoxycytidine (5-Aza). In vivo administration of low doses of 5-Aza induced CCRL2 upregulation, increased recruitment of NK cells, and reduced lung tumor growth. These results identify CCRL2 as an NK-cell lung homing molecule that has the potential to be exploited to promote NK cell-mediated lung immune surveillance.

Identifiants

pubmed: 37343073
pii: 727391
doi: 10.1158/2326-6066.CIR-22-0951
doi:

Substances chimiques

Receptors, CCR 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1280-1295

Informations de copyright

©2023 American Association for Cancer Research.

Auteurs

Francesca Sozio (F)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Tiziana Schioppa (T)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Mattia Laffranchi (M)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Valentina Salvi (V)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Nicola Tamassia (N)

Department of Medicine, Section of General Pathology, University of Verona, Italy.

Francisco M Bianchetto-Aguilera (FM)

Department of Medicine, Section of General Pathology, University of Verona, Italy.

Laura Tiberio (L)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Raffaella Bonecchi (R)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Daniela Bosisio (D)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Marc Parmentier (M)

WELBIO and I.R.I.B.H.M., Université Libre de Bruxelles, Brussels, Belgium.

Barbara Bottazzi (B)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Roberto Leone (R)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Eleonora Russo (E)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Giovanni Bernardini (G)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Stefano Garofalo (S)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.

Cristina Limatola (C)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
IRCCS Neuromed, Pozzilli (IS), Italy.

Angela Gismondi (A)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Giuseppe Sciumè (G)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.

Alberto Mantovani (A)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.

Annalisa Del Prete (A)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Silvano Sozzani (S)

Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur-Italia, Rome, Italy.
IRCCS Neuromed, Pozzilli (IS), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH